Journal of the Korean Medical Association (대한의사협회지)

Korean Medical Association (대한의사협회)
권호 표지
DOI QR코드

DOI QR Code

Essence of preconception counseling and care

임신 전 여성의 관리

  • Hong, Soon-Cheol (Korean Motherisk Program, Department of Obstetrics and Gynecology, Korea University College of Medicine) ;
  • Choi, June Seek (Korean Motherisk Program, Department of Obstetrics and Gynecology, Cheil Hospital & Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Han, Jung Yeol (Korean Motherisk Program, Department of Obstetrics and Gynecology, Cheil Hospital & Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Nava-Ocampo, Alejandro A (The Motherisk Program, Division of Clinical Pharmacology & Toxicology, Hospital for Sick Children) ;
  • Gideon, Koren (The Motherisk Program, Division of Clinical Pharmacology & Toxicology, Hospital for Sick Children)
  • 홍순철 (고려대학교 의과대학 산부인과 한국 마더리스크 프로그램) ;
  • 최준식 (관동대학교 제일병원 산부인과 한국 마더리스크 프로그램) ;
  • 한정열 (관동대학교 제일병원 산부인과 한국 마더리스크 프로그램) ;
  • ;
  • Published : 2011.08.10
⟨ Previous Next ⟩

Abstract

Since the 1980's, prenatal care for pregnant women and their babies has improved maternal and neonatal health. However, despite prenatal care, the rate of some complications, such as major fetal anomalies, preterm labor, and low birth weight have not improved. Only 10.3% of Korean women of childbearing age take folic acid supplementation and approximately 14% still consume alcohol during pregnancy. Because in Korea about 50% of pregnancies are unintended, those women have higher exposure rates to alcohol, drugs, and ionizing radiation. Because most fetal anomalies occur between 5 to 10 gestational weeks, the initial prenatal care provided at 7 to 8 gestational weeks is too late to prevent fetal anomalies. Preconception care may identify and modify adverse health, behavioral, and social outcomes for women and their unborn babies. Recently, a number of preconception interventions have been reported to have evidence-based effectiveness in improving pregnancy outcomes. These include folic acid supplementation, avoiding alcohol intake, smoking cessation, counseling on potentially teratogenic drugs, infection control, immunizations, and control of chronic diseases such as diabetes, hypothyroidism, obesity. For the improvement of maternal and fetal health, guidelines for preconception care must be developed in Korea. All health care providers should understand the clinical importance of evidence-based preconception care.

Keywords

References

  1. Preconception health and care [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2006 [cited 2011 Jul 12]. Available from: http://www.cdc.gov/ncbddd/precon ception/documents/At-a-glance-4-11-06.pdf.
  2. Han JY, Nava-Ocampo AA, Koren G. Unintended pregnancies and exposure to potential human teratogens. Birth Defects Res A Clin Mol Teratol 2005;73:245-248. https://doi.org/10.1002/bdra.20132
  3. Yang JH, Kim YJ, Chung JH, Kim MY, Ryu HM, Ahn HK, Han JY, Yang SH, Kim A, Kim HS, Lee PJ, Kim SS, Kim YJ, Koh KS, Shin JC, Cho YK, Yoon BH. A multi-center study for birth defect monitoring systems in Korea. J Korean Med Sci 2004;19: 509-513. https://doi.org/10.3346/jkms.2004.19.4.509
  4. Kim MH, Han JY, Cho YJ, Ahn HK, Kim JO, Ryu HM, Kim MY, Yang JH, Nava-Ocampo AA. Factors associated with a positive intake of folic acid in the periconceptional period among Korean women. Public Health Nutr 2009;12:468-471. https://doi.org/10.1017/S1368980008002115
  5. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW. Possible prevention of neuraltube defects by periconceptional vitamin supplementation. Lancet 1980;1:339-340.
  6. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995;6:219-226. https://doi.org/10.1097/00001648-199505000-00005
  7. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991;338:131-137. https://doi.org/10.1016/0140-6736(91)90133-A
  8. Czeizel AE, Dudas I. Prevention of the first occurrence of neural- tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-1835. https://doi.org/10.1056/NEJM199212243272602
  9. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992;41(RR-14):1-7.
  10. Van Rooij IA, Ocke MC, Straatman H, Zielhuis GA, Merkus HM, Steegers-Theunissen RP. Periconceptional folate intake by supplement and food reduces the risk of nonsyndromic cleft lip with or without cleft palate. Prev Med 2004;39:689-694. https://doi.org/10.1016/j.ypmed.2004.02.036
  11. Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a metaanalysis. J Obstet Gynaecol Can 2006;28:680-689.
  12. Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet 2001;358:2069-2073. https://doi.org/10.1016/S0140-6736(01)07104-5
  13. Koren G, Goh YI, Klieger C. Folic acid: the right dose. Can Fam Physician 2008;54:1545-1547.
  14. Wilson RD, Johnson JA, Wyatt P, Allen V, Gagnon A, Langlois S, Blight C, Audibert F, Désilets V, Brock JA, Koren G, Goh YI, Nguyen P, Kapur B; Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada and The Motherrisk Program. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2007; 29:1003-1026.
  15. Han JY, Cho YK, Hong DS, Chun JM, Lim OR, Choi JS, Lee HC, Hong SC, Ahn HK, Han YS. Maternal-fetal toxicology. Seoul: Kunja Press; 2009. 806 p.
  16. Choi JS, Han JY, Ahn HK, Lee SW, Kim MH, Chung JH, Ryu HM, Kim MY, Yang JH, Choi KH, Han HW, Kim SH, Lee MB, Han YJ, Choi NM, Cho YK, Young LS, Hong DS, Lim OR, Hong SC. Pregnancy outcomes after peri-conceptional medication exposure: 10 years experience: Study for Application of Reproductive Toxicity Information. Korean J Perinatol 2010;21:48-58.
  17. Yaffe SJ, Briggs GG. Is this drug going to harm my baby? Contemp Ob Gyn 2003;48:57.
  18. Henderson J, Gray R, Brocklehurst P. Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. BJOG 2007;114:243-252. https://doi.org/10.1111/j.1471-0528.2006.01163.x
  19. Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973;302:999-1001. https://doi.org/10.1016/S0140-6736(73)91092-1
  20. Centers for Disease Control and Prevention (CDC). Alcohol use among women of childbearing age--United States, 1991- 1999. MMWR Morb Mortal Wkly Rep 2002;51:273-276.
  21. Koren G, Nulman I. The Motherisk guide to diagnosing fetal alcohol spectrum disorder. Toronto: The Hospital for Sick Children; 2002.
  22. Koren G, Nulman I, Chudley AE, Loocke C. Fetal alcohol spectrum disorder. CMAJ 2003;169:1181-1185.
  23. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J; U.S. Preventive Services Task Force. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:557-568. https://doi.org/10.7326/0003-4819-140-7-200404060-00017
  24. Rogers JM. Tobacco and pregnancy: overview of exposures and effects. Birth Defects Res C Embryo Today 2008;84:1-15. https://doi.org/10.1002/bdrc.20119
  25. Aubard Y, Magne I. Carbon monoxide poisoning in pregnancy. BJOG 2000;107:833-838. https://doi.org/10.1111/j.1471-0528.2000.tb11078.x
  26. ACOG Committee on Health Care for Underdeserved Women; ACOG Committee on Obstetric Practice. ACOG committee opinion. Number 316, October 2005. Smoking cessation during pregnancy. Obstet Gynecol 2005;106:883-888. https://doi.org/10.1097/00006250-200510000-00052
  27. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992;26: 599-606. https://doi.org/10.1016/0190-9622(92)70088-W
  28. Perlman SE, Leach EE, Dominguez L, Ruszkowski AM, Rudy SJ. "Be smart, be safe, be sure". The revised Pregnancy Prevention Program for women on isotretinoin. J Reprod Med 2001;46(2 Suppl):179-185.
  29. Garcia-Bournissen F, Tsur L, Goldstein LH, Staroselsky A, Avner M, Asrar F, Berkovitch M, Straface G, Koren G, De Santis M. Fetal exposure to isotretinoin-an international problem. Reprod Toxicol 2008;25:124-128. https://doi.org/10.1016/j.reprotox.2007.10.005
  30. Nakane Y, Okuma T, Takahashi R, Sato Y, Wada T, Sato T, Fukushima Y, Kumashiro H, Ono T, Takahashi T, Aoki Y, Kazamatsuri H, Inami M, Komai S, Seino M, Miyakoshi M, Tanimura T, Hazama H, Kawahara R, Otsuki S, Hosokawa K, Inanaga K, Nakazawa Y, Yamamoto K. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980; 21:663-680. https://doi.org/10.1111/j.1528-1157.1980.tb04320.x
  31. Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I. Motherisk update: major malformation with valproic acid. Can Fam Physician 2006;52:441-447.
  32. Gaily E, Kantola-Sorsa E, Hiilesmaa V, Isoaho M, Matila R, Kotila M, Nylund T, Bardy A, Kaaja E, Granström ML. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32. https://doi.org/10.1212/WNL.62.1.28
  33. Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs 2007;67:2727-2746. https://doi.org/10.2165/00003495-200767180-00007
  34. Koren G. Maternal-fetal toxicology: a clinician's guide. 3rd ed. New York: Marcel Dekker Inc.; 2001.
  35. Pauli RM, Haun J. Intrauterine effects of coumarin derivatives. Dev Brain Dysfunct 1993;6:229-247.
  36. Van Driel D, Wesseling J, Sauer PJ, Touwen BC, van der Veer E, Heymans HS. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology 2002;66:127-140. https://doi.org/10.1002/tera.10054
  37. Berkowitz RL, Coustan DR, Mochizuki TK. Handbook for prescribing medications during pregnancy. 2nd ed. Boston: Little, Brown; 1986.
  38. Cotrufo M, De Feo M, De Santo LS, Romano G, Della Corte A, Renzulli A, Gallo C. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002;99:35-40. https://doi.org/10.1016/S0029-7844(01)01658-1
  39. Van Driel D, Wesseling J, Sauer PJ, van Der Veer E, Touwen BC, Smrkovsky M. In utero exposure to coumarins and cognition at 8 to 14 years old. Pediatrics 2001;107:123-129. https://doi.org/10.1542/peds.107.1.123
  40. Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association/American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003;41: 1633-1652. https://doi.org/10.1016/S0735-1097(03)00416-9
  41. Lewis JH. Summary of the 29th meeting of the Gastrointestinal Drugs Advisory Committee, Food and Drug Administration-- June 10, 1985. Am J Gastroenterol 1985;80:743-745.
  42. Bond GR, Van Zee A. Overdosage of misoprostol in pregnancy. Am J Obstet Gynecol 1994;171:561-562. https://doi.org/10.1016/0002-9378(94)90302-6
  43. Da Silva Dal Pizzol T, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol 2006;22:666-671. https://doi.org/10.1016/j.reprotox.2006.03.015
  44. Miller G. Neurological disorders. The mystery of the missing smile. Science 2007;316:826-827. https://doi.org/10.1126/science.316.5826.826
  45. Schuller L, Pastuszak AL, Sanseverino MT, Orioli IM, Brunoni D, Koren G. Pregnancy outcome after abortion attempt with misoprostol. Teratology 1997;55:36.
  46. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1-64.
  47. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982;2:781-784.
  48. Cho HJ, Jung H, Lee CG. A study on seroprevalence of rubella specific antibody in Korean college women. Korean J Obstet Gynecol 2005;48:732-740.
  49. Haas DM, Flowers CA, Congdon CL. Rubella, rubeola, and mumps in pregnant women: susceptibilities and strategies for testing and vaccinating. Obstet Gynecol 2005;106:295-300. https://doi.org/10.1097/01.AOG.0000171110.49973.e3
  50. National Collaborating Centre for Women's and Children's Health. Antenatal care: routine care for the healthy pregnant woman. London: RCOG Press; 2008.
  51. Sathanandan D, Gupta L, Liu B, Rutherford A, Lane J. Factors associated with low immunity to rubella infection on antenatal screening. Aust N Z J Obstet Gynaecol 2005;45:435-438. https://doi.org/10.1111/j.1479-828X.2005.00467.x
  52. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996; 45:1-36.
  53. Auriti C, Piersigilli F, De Gasperis MR, Seganti G. Congenital varicella syndrome: still a problem? Fetal Diagn Ther 2009;25: 224-229. https://doi.org/10.1159/000220602
  54. Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol 2006;21:410-420. https://doi.org/10.1016/j.reprotox.2005.04.011
  55. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534. https://doi.org/10.1001/archinte.160.4.526
  56. Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002;12:63-68. https://doi.org/10.1089/105072502753451986
  57. Matalon S, Sherner E, Levy A. Relationship of treated maternal hypothyroidism and perinatal outcome. J Reprod Med 2006;51:59-63.
  58. Delange F. The disorders induced by iodine deficiency. Thyroid 1994;4:107-128. https://doi.org/10.1089/thy.1994.4.107
  59. Pop VJ, Kuijpens JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, Vulsma T, Wiersinga WM, Drexhage HA, Vader HL. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf) 1999;50:149-155. https://doi.org/10.1046/j.1365-2265.1999.00639.x
  60. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999;341:549-555. https://doi.org/10.1056/NEJM199908193410801
  61. Utiger RD. Maternal hypothyroidism and fetal development. N Engl J Med 1999;341:601-602. https://doi.org/10.1056/NEJM199908193410809
  62. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457-469.
  63. Hanson U, Persson B. Outcome of pregnancies complicated by type 1 insulin-dependent diabetes in Sweden: acute pregnancy complications, neonatal mortality and morbidity. Am J Perinatol 1993;10:330-333. https://doi.org/10.1055/s-2007-994754
  64. Dunlop AL, Jack BW, Bottalico JN, Lu MC, James A, Shellhaas CS, Hallstrom LH, Solomon BD, Feero WG, Menard MK, Prasad MR. The clinical content of preconception care: women with chronic medical conditions. Am J Obstet Gynecol 2008;199(6 Suppl 2):S310-S327. https://doi.org/10.1016/j.ajog.2008.08.031
  65. Mahmud M, Mazza D. Preconception care of women with diabetes: a review of current guideline recommendations. BMC Womens Health 2010;10:5. https://doi.org/10.1186/1472-6874-10-5
  66. Roland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC. The pregnancies of women with type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med 2005;22:1774-1777. https://doi.org/10.1111/j.1464-5491.2005.01784.x
  67. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health. Obes Res 1998;6 Suppl 2:51S-209S.
  68. Sebire NJ, Jolly M, Harris JP, Wadsworth J, Joffe M, Beard RW, Regan L, Robinson S. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord 2001;25:1175-1182. https://doi.org/10.1038/sj.ijo.0801670
  69. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal obesity and risk for birth defects. Pediatrics 2003;111(5 Part 2):1152-1158.
  70. McTigue KM, Harris R, Hemphill B, Lux L, Sutton S, Bunton AJ, Lohr KN. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;139:933-949. https://doi.org/10.7326/0003-4819-139-11-200312020-00013

Cited by

  1. 수태 전 건강관리에 대한 젠더 간 인식 차이 vol.19, pp.4, 2011, https://doi.org/10.4069/kjwhn.2013.19.4.219
  2. 예비 신혼부부의 수태 전 건강관리 인식수준과 생식 건강증진 행위에 관한 연구 vol.21, pp.2, 2011, https://doi.org/10.4069/kjwhn.2015.21.2.71
  3. 고령임산부의 임신과 출산 건강관리 요구 vol.21, pp.4, 2011, https://doi.org/10.4069/kjwhn.2015.21.4.332
  4. A Prospective Study on Serum Methylmalonic Acid and Homocysteine in Pregnant Women vol.8, pp.12, 2016, https://doi.org/10.3390/nu8120797
  5. 임신 중 흡연에 의한 태아학대: 태아생존권 옹호를 위한 접근 vol.22, pp.4, 2016, https://doi.org/10.4094/chnr.2016.22.4.317
  6. Korean Mothersafe Center 10th Anniversary: Outcome and Future Prospects vol.23, pp.4, 2011, https://doi.org/10.21896/jksmch.2019.23.4.209